PRKCA and cancer: Furthermore, small molecular compounds such as curcumin and histone deacetylase inhibitors present anti‐cancer activity by inhibiting WT1 expression through the PKCα signalling pathway29; histone deacetylase inhibitors like trichostatin A down‐regulates WT1 expression partially through ubiquitin‐conjugating enzyme UbcH8.30 These results indicate that WT1 might be a suitable target for cancer therapy.